Challenges and opportunities for implementing hypofractionated radiotherapy in Africa: lessons from the HypoAfrica clinical trial.
Challenges and opportunities for implementing hypofractionated radiotherapy in Africa: lessons from the HypoAfrica clinical trial.
复制标题
DOI：
10.3332/ecancer.2023.1508
复制
发表时间：
2023
影响因子：
1.8
通讯作者：
Ngw, Wifered
中科院分区：
文献类型：
--
作者：
Olatunji, Elizabeth;Swanson, William;Patel, Saloni;Adeneye, Samuel Olaolu;Aina-Tofolari, Funmilayo;Avery, Stephen;Kisukari, Jumaa Dachi;Graef, Katy;Huq, Saiful;Jeraj, Robert;Joseph, Adedayo;Lehmann, Joerg;Li, Heng;Mallum, Abba;Mkhize, Thokozani;Ngoma, Twalib Athumani;Studen, Andrej;Wijesooriya, Krishni;Incrocci, Luca;Ngw, Wifered
撒哈拉以南非洲（SSA）的癌症发病率和死亡率不断上升，因此需要更加注重采用或开发能够显著增加该地区治疗可及性的方法。最近《柳叶刀》肿瘤学委员会为撒哈拉以南非洲推荐的一种这样的方法是低分割放射治疗（HFRT），它可以通过减少每个人接受治疗的总时间（以天为单位）大大增加获得放射治疗的机会。在这里，我们强调在实施HypoAfrica临床试验期间采用这种方法所面临的挑战。HypoAfrica临床试验是一项纵向、多中心研究，探索在SSA中应用HFRT治疗前列腺癌的可行性。这项研究提供了一个机会，对采用HFRT的潜在障碍和促进因素进行务实评估。我们的研究结果突出了三个关键挑战：质量保证、研究协调和机器维护。我们描述了用于解决这些挑战和机会的长期解决方案，这些解决方案可以促进在SSA临床护理和多中心临床试验中扩大HFRT的使用。本报告为放疗方法的使用提供了有价值的参考，增加了治疗的可及性，并开展了涉及放疗的高质量大规模/多中心临床试验。还没有。
The rising cancer incidence and mortality in sub-Saharan Africa (SSA) warrants an increased focus on adopting or developing approaches that can significantly increase access to treatment in the region. One such approach recommended by the recent Lancet Oncology Commission for sub-Saharan Africa is hypofractionated radiotherapy (HFRT), which can substantially increase access to radiotherapy by reducing the overall duration of time (in days) each person spends being treated. Here we highlight challenges in adopting such an approach identified during the implementation of the HypoAfrica clinical trial. The HypoAfrica clinical trial is a longitudinal, multicentre study exploring the feasibility of applying HFRT for prostate cancer in SSA. This study has presented an opportunity for a pragmatic assessment of potential barriers and facilitators to adopting HFRT. Our results highlight three key challenges: quality assurance, study harmonisation and machine maintenance. We describe solutions employed to resolve these challenges and opportunities for longer term solutions that can facilitate scaling-up use of HFRT in SSA in clinical care and multicentre clinical trials. This report provides a valuable reference for the utilisation of radiotherapy approaches that increase access to treatment and the conduct of high-quality large-scale/multi-centre clinical trials involving radiotherapy. Not available yet.
登录
查看更多内容
影响因子：
4.7
作者：
Swanson W;Kamwa F;Samba R;Ige T;Lasebikan N;Mallum A;Ngoma T;Sajo E;Elzawawy A;Incrocci L;Ngwa W
通讯作者：
Ngwa W
影响因子：
3
作者：
Nelson EK;Piehler B;Eckels J;Rauch A;Bellew M;Hussey P;Ramsay S;Nathe C;Lum K;Krouse K;Stearns D;Connolly B;Skillman T;Igra M
通讯作者：
Igra M
DOI：
10.1007/s00259-021-05650-3
发表时间：
2022-05
影响因子：
9.1
作者：
Hribernik, Nezka;Huff, Daniel T.;Studen, Andrej;Zevnik, Katarina;Klanecek, Zan;Emamekhoo, Hamid;Skalic, Katja;Jeraj, Robert;Rebersek, Martina
通讯作者：
Rebersek, Martina
影响因子：
4.5
作者：
Leng, Jim;Ntekim, Atara, I;Olopade, Olufunmilayo, I
通讯作者：
Olopade, Olufunmilayo, I
DOI：
10.1016/s1470-2045(16)30102-4
发表时间：
2016-08
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Dearnaley D;Syndikus I;Mossop H;Khoo V;Birtle A;Bloomfield D;Graham J;Kirkbride P;Logue J;Malik Z;Money-Kyrle J;O'Sullivan JM;Panades M;Parker C;Patterson H;Scrase C;Staffurth J;Stockdale A;Tremlett J;Bidmead M;Mayles H;Naismith O;South C;Gao A;Cruickshank C;Hassan S;Pugh J;Griffin C;Hall E;CHHiP Investigators
通讯作者：
CHHiP Investigators